№ lp_2_1_19780
File format: docx
Character count: 12626
File size: 28 KB
This document is a research article discussing gene expression data, clinical information, and experimental results related to liver fibrosis and hepatocellular carcinoma (HCC) from various datasets and patient samples.
Year:
2023
Region / City:
Wuhan, China
Topic:
Gene expression, liver fibrosis, HCC
Document Type:
Research Article
Organization / Institution:
Zhongnan Hospital of Wuhan University, Wuhan University
Author:
Not specified
Target Audience:
Researchers, clinicians, medical professionals
Duration:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Context
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2020
Region / City:
Houston
Theme:
Resume guidelines
Document type:
Guidelines
Organization / Institution:
Houston Community College
Author:
Career Services
Target audience:
Students
Period of validity:
N/A
Approval date:
N/A
Date of changes:
N/A
Year:
2021
Region / city:
University of Washington Medical Center
Topic:
Diagnostic Ultrasound Protocol
Document Type:
Protocol
Organization:
University of Washington Medical Center
Author:
Unknown
Target Audience:
Medical Professionals
Period of validity:
Not specified
Approval Date:
10/25/2021
Date of changes:
10/25/2021
Context:
A medical protocol detailing diagnostic ultrasound procedures for screening of liver conditions including Hepatocellular Carcinoma (HCC) and Right Upper Quadrant (RUQ) evaluation at the University of Washington Medical Center.
Year:
2019
Region / City:
Washington, D.C., District of Columbia; California; Princeton, New Jersey; New York, New York; Nashville, Tennessee; Boston, Massachusetts; North Carolina; New Britain, Connecticut
Field:
Public Health, Healthcare
Document Type:
Internship Program Announcement
Organization:
HCC (Health Career Connection)
Author:
Health Career Connection
Target Audience:
Undergraduate students, recent college graduates
Period of Action:
Summer 2019
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2019-2020
Region / City:
Shanghai, China
Field:
Medical research, oncology
Document type:
Research article
Institution:
Zhongshan Hospital Fudan University
Authors:
Not specified
Target audience:
Researchers, medical professionals
Study period:
May 2019 - February 2020
Approval date:
B2019-060R
Follow-up end date:
March 31, 2020
Year:
2024
Region / City:
Jefferson County, Alabama
Topic:
Emergency Healthcare Coordination
Document Type:
Response Plan
Organization:
Jefferson County Health Care Coalition
Author:
HCC Readiness and Response Coordinator, J. Cobb, RN
Target Audience:
Healthcare Providers, Emergency Response Teams
Period of Effectiveness:
Ongoing, with annual updates
Approval Date:
March 2024
Date of Changes:
March 2024
Year:
2010-2024
Region / city:
Asia-Pacific
Subject:
Hepatology
Document Type:
Clinical Practice Guidelines
Organization / Institution:
Asian Pacific Association for the Study of the Liver (APASL)
Author:
APASL
Target Audience:
Healthcare professionals
Period of validity:
2010-2024
Date of approval:
2010
Date of revisions:
2024
Context:
Collection of clinical practice guidelines and consensus statements issued by the Asian Pacific Association for the Study of the Liver on various hepatological conditions, including hepatocellular carcinoma, hepatitis B and C, liver transplantation, and metabolic diseases.
Year:
2024
Region / City:
Nanfang Hospital
Theme:
Hepatology, Cancer Diagnosis
Document Type:
Scientific Methodology
Institution:
Nanfang Hospital
Author:
Unspecified
Target Audience:
Medical Professionals, Researchers
Period of Action:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Context:
This document presents the diagnostic criteria for cirrhosis and hepatocellular carcinoma, including imaging techniques and laboratory results, based on a multi-center study with radiomics and deep learning features for prediction models.
Organisation:
Hampshire County Council
Service:
HCC Learning Zone
Target Audience:
Hampshire Maintained Schools staff, Headteachers, Line Managers, Delegated Managers, Admin Officers, Business Managers, Governors
Document Type:
Quick Guide
Subject:
System Access, Course Booking, Delegation and Notifications
Access Platforms:
HantsConnect; Shared Services Portal
Related Systems:
ESS Lite; My Learning; My Teams
Contact Reference:
HTLC
Email Notification Address:
[email protected]
Geographical Scope:
Hampshire, United Kingdom
Digital Platform:
Online Learning Management System
Year:
Not specified
Region / City:
Not specified
Subject:
DNA methylation, LRP11, HCC
Document Type:
Supplementary figure
Organization / Institution:
SMART database
Author:
Not specified
Target Audience:
Researchers in genomics
Effective Period:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Document type:
Supplementary table
Subject:
Hepatocellular carcinoma sample cohorts and sequencing methods
Tissue types:
HCC; HCC+NTL
Sequencing methods:
HBV capture; WGS; RNA-seq
Sample cohorts:
Zhao et al.; Péneau et al.; Sung et al.; Candia et al.; Yoo et al.; In-house cohorts
Countries / regions:
Mainland China; France; Hong Kong; Mongolia; United States
Total studies listed:
7 cohorts
Data fields:
Sample size; Tissue type; Sequencing method; Male proportion; Age; Accession number
Data repositories referenced:
SRA; EGA; GEO
Associated identifiers:
PRJNA298941; ERP00196; GSE144269; PRJNA371753
Research context:
Genomic sequencing datasets related to hepatocellular carcinoma
Year:
2014
Region / city:
Qatar
Topic:
Medical Research
Document Type:
Research Article
Author(s):
Atqah AbdulWahab, Saad J Taj-Aldeen, Emad Ibrahim, Shaikha H Abdulla, Ramees Muhammed, Irshad Ahmed, Yasmine Abdeen, Omnia Sadek, Marawan Abu-Madi
Target Audience:
Medical professionals, researchers in infectious diseases
Date of approval:
2014
Note:
Contextual description
Year:
2010-2024
Region / city:
Asia-Pacific
Subject:
Hepatology
Document Type:
Clinical Practice Guidelines
Organization / Institution:
Asian Pacific Association for the Study of the Liver (APASL)
Author:
APASL
Target Audience:
Healthcare professionals
Period of validity:
2010-2024
Date of approval:
2010
Date of revisions:
2024
Context:
Collection of clinical practice guidelines and consensus statements issued by the Asian Pacific Association for the Study of the Liver on various hepatological conditions, including hepatocellular carcinoma, hepatitis B and C, liver transplantation, and metabolic diseases.
Authors:
Noelia Rodriguez Mier; Senne Cuyx; Kris De Boeck; Marijke Proesmans; Mieke Boon; Lieven Dupont; Kaline Arnauts; Elke De Wachter; Stephanie Van Biervliet; Monique Lequesne; Vicky Nowé; Hedwige Boboli; Anabela Santo Ramalho; François Vermeulen; on behalf of the Belgian Organoid Project
Affiliations:
KU Leuven; University Hospital Leuven; University Hospital Brussels; Ghent University Hospital; Antwerp University Hospital; GZA Hospital; CHR Citadelle
Country:
Belgium
Research field:
Cystic fibrosis; CFTR modulators; organoid research; personalized medicine
Study population:
60 people with cystic fibrosis homozygous for F508del
Genetic focus:
F508del CFTR mutation (homozygous)
Interventions studied:
Elexacaftor/tezacaftor/ivacaftor; Tezacaftor/ivacaftor
Methods:
Patient-derived intestinal organoids from rectal biopsies; forskolin-induced swelling assay; comparison with clinical outcomes
Clinical outcomes assessed:
Lung function; sweat chloride levels; body weight; pulmonary exacerbations
Type of document:
Scientific research article
Source:
PubMed
DOI / Identifier:
40883119
Medicine:
Pirfenidone 267 mg capsule
Brand name:
Esbriet®
Manufacturer:
Roche Products Pty Ltd
Quantity:
270 capsules
Maximum quantity:
1
Number of repeats:
5
Program:
Section 100 – Highly Specialised Drugs Program
Schedule:
General Schedule (Code GE)
Condition:
Idiopathic pulmonary fibrosis
Treatment phases:
Initial treatment; Continuing treatment; Initial PBS-subsidised treatment (grandfather patient)
Restriction level:
Restricted benefit – Authority Required
Authority method:
In Writing; Telephone; Emergency; Electronic; Streamlined
Prescriber requirement:
Respiratory physician or specialist physician experienced in idiopathic pulmonary fibrosis
Population criteria:
Patients aged 40 years or older
Clinical criteria (initial):
Confirmed diagnosis of idiopathic pulmonary fibrosis supported by HRCT with or without surgical lung biopsy; FVC ≥ 50%; DLCO ≥ 30%
Clinical criteria (continuing):
Prior PBS-subsidised treatment with pirfenidone
Administrative authority:
Department of Human Services, Australia
Application requirement:
Completed authority prescription form and IPF Initial PBS authority application form with supporting diagnostic documentation
Geographical reference:
Hobart, TAS 7001, Australia
Year:
2023
Region / City:
Royal Devon & Exeter Hospital, Wonford, UK
Topic:
Healthcare, Physiotherapy
Document Type:
Job Description
Organization / Institution:
Royal Devon University Healthcare NHS Foundation Trust
Author:
N/A
Target Audience:
Healthcare professionals, physiotherapists
Period of Validity:
N/A
Approval Date:
N/A
Amendment Date:
N/A
Authors:
Petar Avramovski; Julijana Petrovska; Maja Avramovska
Affiliations:
St. Clement of Ohrid University – Bitola; Clinical Hospital – Bitola
Country:
North Macedonia
City:
Bitola
Medical Field:
Gastroenterology; Hepatology; Diagnostic Ultrasound
Type of Document:
Scientific research abstract
Study Design:
Observational clinical study
Study Population:
325 patients with non-alcoholic fatty liver disease (NAFLD)
Average Age of Participants:
54.2±8.5 years
Institutions Involved:
Department of Ultrasonography; Department of Gastroenterohepatology; Department of Gynecology and Obstetrics, Clinical Hospital – Bitola
Methods:
B-mode ultrasound imaging, echogenicity analysis software, laboratory tests for platelets, ALT and AST, calculation of FIB-4 score
Diagnostic Indicators Studied:
Hepatorenal Index (HRI); Fibrosis-4 (FIB-4) score
Conditions Examined:
Non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; liver fibrosis; cirrhosis
Patient Group Classification:
Mild NAFLD; moderate NAFLD; severe NAFLD; significant fibrosis (≥F2); advanced fibrosis (≥F3); cirrhosis (F4)
Keywords:
hepatorenal index; FIB-4 score; NAFLD; liver fibrosis; cirrhosis; ultrasound diagnostics
Year:
2025
Organization:
Alder Hey Children’s NHS Foundation Trust
Department:
Department of Respiratory Medicine
Document type:
Patient information leaflet
Target audience:
Patients, parents and carers of children with cystic fibrosis
Topic:
Genetics of cystic fibrosis, carrier testing, reproductive options
Review date:
March 2025
Contact:
Tel: 0151 228 4811, www.alderhey.nhs.uk
Location:
Liverpool, United Kingdom
Year:
2023
Location:
Tarrytown, NY, USA
Subject:
Medical diagnostics, liver disease
Document type:
Press release
Organization:
Siemens Healthcare Diagnostics Inc.
Author:
Kimberly Nissen
Target audience:
Healthcare professionals, journalists
Regulatory status:
FDA Breakthrough Device Designation
Test:
Enhanced Liver Fibrosis (ELF™) Test
Biomarkers:
Hyaluronic acid (HA), Procollagen III amino-terminal peptide (PIIINP), Tissue inhibitor of metalloproteinase 1 (TIMP-1)
Clinical relevance:
Identification of advanced fibrosis and cirrhosis in NAFLD/NASH patients
Date issued:
July 18, 2023
Associated guidelines:
American Diabetes Association, American Association of Clinical Endocrinology, American Gastroenterological Association, American Association for the Study of Liver Diseases
Year:
2016
Author:
Tamia Jackson
Date:
March 11, 2016
Period/Class:
5th period
Topic:
Cystic Fibrosis
Document Type:
Educational overview
Intended Audience:
Students
Key Subjects:
Genetic causes, airway clearance, inhaled medications, nutrition, fitness, CFTR modulators, lung transplantation
Related Conditions:
Fibrocystic Disease of the pancreas, Mucoviscidosis
Medical Note:
There is no cure for Cystic Fibrosis
Year:
Not specified
Region / Area:
Europe
Subject:
Post-authorisation safety and efficacy studies in cystic fibrosis registries
Document Type:
Application form
Organization:
European Cystic Fibrosis Society Patient Registry (ECFSPR)
Related Organization:
European Medicines Agency (EMA)
Applicant Type:
Marketing Authorisation Holder
Purpose:
Submission of requests for registry data for PASS / PAES studies
Required Attachments:
Study protocol; Statistical analysis plan
Submission Method:
Email submission to [email protected]
Key Sections:
Applicant details; Study information; Cohort definition; Statistical methods; Data requirements
Population Scope:
Patients included in the European Cystic Fibrosis Society Patient Registry
Historical Data Availability:
2008–2023
Fee Structure:
€5,000 handling; €25,000 review and feasibility assessment; €5,000 application modification
Governance Note:
Individual country applications outside ECFSPR governance may apply separate fees